{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-315472","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2021-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.488535+00:00","generated_at":"2026-06-28T15:40:31.651376+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aadi appoints Scott Giacobello as CFO, replacing interim CFO Lance Thibault","bullets":["Scott Giacobello appointed CFO and Treasurer, effective Nov 28, 2021; part-time from Nov 1.","Compensation: $450k base salary, bonus up to 45% of base, and option for 200k shares vesting over 4 years.","Giacobello was CFO of GW Pharma (acquired by Jazz for $7.2B); led EPIDIOLEX launch with $296M first-year sales.","Company faces PDUFA date Nov 26, 2021 for lead drug FYARRO in malignant PEComa.","Lance Thibault, interim CFO since July 2021, will leave the role on the effective date."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-315472","json":"https://secwatch.observer/filing/0001193125-21-315472.json","markdown":"https://secwatch.observer/filing/0001193125-21-315472.md","text":"https://secwatch.observer/filing/0001193125-21-315472.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521315472/0001193125-21-315472-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521315472/d173598d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T15:40:31.651376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"124acdf64f","claim":"Scott Giacobello was appointed as Chief Financial Officer and Treasurer at Whitehawk Therapeutics, Inc..","evidence_excerpt":"appointed Scott Giacobello as its Chief Financial Officer and Treasurer, effective November 28, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521315472/0001193125-21-315472-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer and Treasurer"}],"fact_type":"executive_change"},{"claim_id":"157fdb7925","claim":"Lance Thibault departed as interim Chief Financial Officer at Whitehawk Therapeutics, Inc..","evidence_excerpt":"Lance Thibault, who has served as the interim Chief Financial Officer since July 2021, will cease to be the interim Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521315472/0001193125-21-315472-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"cease to be the interim Chief Financial Officer"},{"label":"Role","value":"interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}